Global Clot Busting Drugs Market Size study & Forecast, by Product (Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants, Others) by Indication (Deep Vein Thrombosis, Atrial Fibrillation, Pulmonary Embolism, Others), by Route of Administration (Oral, I

Global Clot Busting Drugs Market Size study & Forecast, by Product (Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants, Others) by Indication (Deep Vein Thrombosis, Atrial Fibrillation, Pulmonary Embolism, Others), by Route of Administration (Oral, Injectable), by Distribution Channel (Hospital Pharmacy, Drug Store, Online Pharmacy, Retail Pharmacy) and Regional Analysis, 2023-2030

Global Clot Busting Drugs Market is valued at approximately USD 28.6 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.2% over the forecast period 2023-2030. Clot-busting drugs are medications used to dissolve blood clots in a medical emergency. These drugs work by activating the body's natural clot-dissolving system, known as fibrinolysis, to break down the fibrin meshwork that forms blood clots. The most used clot-busting drug is tissue plasminogen activator (tPA), also called alteplase. tPA is a naturally occurring protein in the body that helps dissolve blood clots. The Clot Busting Drugs market is expanding because of factors such as the increasing incidence of thrombotic disorders and government initiatives and funding for the development of thrombolytic drugs.

The rising prevalence of cardiovascular diseases, deep vein thrombosis, pulmonary embolism, and ischemic stroke has led to an increased demand for clot-busting drugs. These conditions require immediate treatment to dissolve blood clots and restore blood flow, thereby driving market growth. The Global Stroke Factsheet released in 2022 reveals that the risk for developing stroke has increased by 50% over the last 17 years and as of year 2022, 1 in 4 people is estimated to have a stroke in their lifetime. Furthermore, according to World Health Organization Report 2020 around 17.9 million lives each year are being suffered from heart disorders across the globe. Thus rising prevalence of thrombotic disorders such as cardiovascular diseases and ischemic stroke is driving the market growth. In addition, advancements in clot-busting drug therapies and rising awareness and diagnosis of clotting disorders are creating a lucrative opportunity for market growth. However, the high cost of Clot Busting Drugs and advancements in interventional procedures: stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Clot Busting Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, increasing disease prevalence, and a rising number of research and development activities. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as the rising geriatric, increasing prevalence of diseases, an increase in the number of collaborations for product development, and active participation of government and private organizations in the market space.

Major market players included in this report are:
Bayer AG
Merck & Co
Sun Pharmaceutical Industries Ltd.
Johnson & Johnson Services Inc
Sanofi-Aventis S.A
Boehringer Ingelheim Gmbh
Dr. Reddy’s Laboratories
Genentech Inc.
Pfizer Inc.
Eli Lilly and Company

Recent Developments in the Market:
In December 2021, The U.S. FDA approved XARELTO (rivaroxaban), an oral anticoagulant manufactured by Janssen Pharmaceutical. The medication has two pediatric indications, including the prevention of deep vein thrombosis (DVT) that causes pulmonary embolism.

In June 2021, Boehringer Ingelheim released dabigatran etexilate, the active ingredient in Pradaxa. Pradaxa oral pellets were given FDA approval to treat venous thromboembolism, a condition in which blood clots develop in the veins, in children three months to under twelve years old.

Global Clot Busting Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Indication, Route of Administration, Distribution Channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Thrombolytic Drugs
Anti-Platelet Drugs
Anticoagulants
Others

By Indication:
Deep Vein Thrombosis
Atrial Fibrillation
Pulmonary Embolism
Others

By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacy
Drug Store
Online Pharmacy
Retail Pharmacy

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Bayer AG
Merck & Co
Sun Pharmaceutical Industries Ltd.
Johnson & Johnson Services Inc
Sanofi-Aventis S.A
Boehringer Ingelheim Gmbh
Dr. Reddy’s Laboratories
Genentech Inc.
Pfizer Inc.
Eli Lilly and Company

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.